Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries
Devin D Smith, Jessica L Pippen, Adebayo A Adesomo, Kara M Rood, Mark B Landon, Maged M Costantine, Devin D Smith, Jessica L Pippen, Adebayo A Adesomo, Kara M Rood, Mark B Landon, Maged M Costantine
Abstract
Objective: Pregnant women have been historically excluded from clinical trials for nonobstetric conditions, even during prior epidemics. The objective of this review is to describe the current state of research for pregnant women during the coronavirus disease 2019 (COVID-19) pandemic.
Study design: We conducted a search of international trial registries for trials relating to the novel coronavirus. The eligibility criteria for each trial were reviewed for inclusion/exclusion of pregnant women. Relevant data were extracted and descriptive statistics were calculated for individual and combined data. The total number of trials from each registry were compared, as well as the proportions of pregnancy-related trials within each.
Results: Among 621,370 trials in the World Health Organization International Clinical Trials Registry, 927 (0.15%) were COVID-19 related. Of those, the majority (52%) explicitly excluded pregnancy or failed to address pregnancy at all (46%) and only 16 (1.7%) were pregnancy specific. When categorized by region, 688 (74.2%) of COVID-19 trials were in Asia, followed by 128 (13.8%) in Europe, and 66 (7.2%) in North America. Of the COVID-19 trials which included pregnant women, only three were randomized-controlled drug trials.
Conclusion: Approximately 1.7% of current COVID-19 research is pregnancy related and the majority of trials either explicitly exclude or fail to address pregnancy. Only three interventional trials worldwide involved pregnant women. The knowledge gap concerning the safety and efficacy of interventions for COVID-19 created by the exclusion of pregnant women may ultimately harm them. While "ethical" concerns about fetal exposure are often cited, it is in fact unethical to habitually exclude pregnant women from research.
Key points: · Pregnancy was excluded from past pandemic research.. · Pregnancy is being excluded from COVID-19 research.. · Exclusion of pregnant women is potentially harmful..
Conflict of interest statement
None declared.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Figures
References
- Blehar M C, Spong C, Grady C, Goldkind S F, Sahin L, Clayton J A.Enrolling pregnant women: issues in clinical researchWomen's Heal Issues2013. Doi: 10.1016/j.whi.2012.10.003
- Shields K E, Lyerly A D. Exclusion of pregnant women from industry-sponsored clinical trials. Obstet Gynecol. 2013;122(05):1077–1081.
- Illamola S M, Bucci-Rechtweg C, Costantine M M, Tsilou E, Sherwin C M, Zajicek A. Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. Br J Clin Pharmacol. 2018;84(02):215–222.
- Mitchell A A, Gilboa S M, Werler M M, Kelley K E, Louik C, Hernández-Díaz S; National Birth Defects Prevention Study.Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008 Am J Obstet Gynecol 201120501510–5.1E9.
- Ayad M, Costantine M M. Epidemiology of medications use in pregnancy. Semin Perinatol. 2015;39(07):508–511.
- McCormack S A, Best B M. Obstetric pharmacokinetic dosing studies are urgently needed. Front Pediatr. 2014;2:9.
- Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC). PRGLAC Report to the HHS Secretary and Congress, September 2018.; 2018. Available at:. Accessed April 28, 2020
- Ballantyne A. Pregnant women can finally expect better. Hastings Cent Rep. 2019;49(01):10–11.
- Worldometer.Coronavirus Update (Live): 472,907 Cases and 21,315 Deaths from COVID-19 Virus Outbreak - Worldometer Worldometer; Available at:. Accessed April 28, 2020
- World Health Organization.Coronavirus (COVID-19) events as they happen WHO; Available at:. Accessed April 28, 2020
- WHO.Coronavirus Disease 2019 (COVID-19) Situation Report-79; 2020Available at:. Accessed April 28, 2020
- Gonzalez D, Boggess K A, Cohen-Wolkowiez M. Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy. Obstet Gynecol. 2015;125(04):953–958.
- Gomes M F, de la Fuente-Núñez V, Saxena A, Kuesel A C. Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. Reprod Health. 2017;14 03:172.
- Connor E M, Sperling R S, Gelber R et al.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–1180.
- Nayak S.Influenza vaccine requirements in pregnant womenJ Obstet Gynecol India2016. Doi: 10.1007/s13224-016-0867-1
- Louie J K, Acosta M, Jamieson D J, Honein M A; California Pandemic (H1N1) Working Group.Severe 2009 H1N1 influenza in pregnant and postpartum women in California N Engl J Med 20103620127–35.
- Newsome K, Williams J, Way S et al.Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)--United States, April 2009-August 2010. Morb Mortal Wkly Rep. 2011;60(35):1193–1196.
- Saleeby E, Chapman J, Morse J, Bryant A, Nygaard I. H1N1 influenza in pregnancy: cause for concern. Obstet Gynecol. 2009;114(04):885–891.
- Goldkind S F, Sahin L, Gallauresi B. Enrolling pregnant women in research--lessons from the H1N1 influenza pandemic. N Engl J Med. 2010;362(24):2241–2243.
- McKiever M, Frey H, Costantine M M.Challenges in conducting clinical research studies in pregnant womenJ Pharmacokinet Pharmacodyn2020. Doi: 10.1007/s10928-020-09687-z
- Spong C Y, Bianchi D W. Improving public health requires inclusion of underrepresented populations in research. JAMA. 2018;319(04):337–338.
Source: PubMed